DEA Places Cannabinoid Into Schedule II
The Drug Enforcement Administration is placing the newly approved drug lasmiditan in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective Jan. 31, lasmiditan, which was granted approval by the Food and Drug Administration in October, is subject to new registration, labeling, recordkeeping, and import and export requirements. DEA is accepting comments on the rule until March 2.
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
(Federal Register 01/31/20)